NSAID Guide for Personal Injury Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 11 min read

A comprehensive guide to all NSAIDs prescribed in personal injury -- ibuprofen, naproxen, meloxicam, diclofenac, celecoxib, ketorolac, indomethacin, piroxicam, and etodolac -- comparing OTC vs Rx formulations, COX-1 vs COX-2 selectivity, GI risk profiles, and documentation value for PI cases.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are medications that reduce pain, inflammation, and fever by inhibiting cyclooxygenase (COX) enzymes involved in prostaglandin synthesis. In personal injury cases, NSAIDs are the single most frequently prescribed drug class because inflammation is the body's immediate response to traumatic injury, and controlling that inflammation is foundational to every PI treatment plan.

• NSAIDs are the most commonly prescribed drug class in PI cases, treating the acute inflammation that accompanies virtually every traumatic injury
• The class divides into non-selective COX inhibitors (ibuprofen, naproxen, meloxicam, diclofenac, ketorolac, indomethacin, piroxicam, etodolac) and selective COX-2 inhibitors (celecoxib)
• OTC-strength NSAIDs (ibuprofen 200 mg, naproxen 220 mg) differ clinically from prescription-strength formulations, and the escalation from OTC to Rx is a documented severity indicator
• GI risk profiles vary significantly across the class, and co-prescription of GI protective agents like omeprazole documents both injury severity and appropriate medical management
• LienScripts documents every NSAID prescription fill through its pharmacy lien program, creating timestamped evidence of ongoing inflammatory injury

COX-1 vs COX-2: Understanding the Mechanism

All NSAIDs work by inhibiting cyclooxygenase enzymes. Two isoforms matter clinically:

COX-1 is constitutively expressed throughout the body, including the gastric mucosa, platelets, and kidneys. Inhibiting COX-1 produces anti-inflammatory and analgesic effects but also reduces the protective prostaglandins that maintain the stomach lining -- which is why traditional NSAIDs carry GI bleeding risk.

COX-2 is primarily induced at sites of inflammation and tissue injury. Selective COX-2 inhibition targets pain and inflammation while preserving more of the gastric protective mechanisms. Celecoxib (Celebrex) is the only selective COX-2 inhibitor currently available in the United States.

This distinction matters in PI cases because the choice between a non-selective NSAID and celecoxib reflects the physician's assessment of the patient's GI risk profile alongside the inflammatory injury being treated.

Comprehensive Comparison: All NSAIDs in PI Practice

OTC vs Prescription: Why the Escalation Matters

One of the most clinically significant patterns in PI pharmacy records is the transition from over-the-counter NSAID use to prescription-strength formulations. This escalation documents several things simultaneously:

The injury exceeded self-care capacity. When a patient moves from OTC ibuprofen 200 mg to prescription ibuprofen 800 mg, the physician has determined that consumer-strength anti-inflammatory therapy is insufficient for the level of inflammation present.

The physician assessed and documented the need. Prescription NSAIDs require a clinical encounter, examination findings, and a prescribing decision. Each prescription is a medical judgment linked to documented pathology.

Higher doses require medical monitoring. Prescription-strength NSAIDs carry greater GI, renal, and cardiovascular risk, which is why they require physician oversight. The decision to accept these risks reflects the physician's judgment that the inflammatory injury warrants more aggressive treatment.

When Physicians Prescribe Each NSAID

Ibuprofen and Naproxen: The Foundation

Ibuprofen and naproxen are the workhorses of PI anti-inflammatory treatment. At prescription strength, they provide reliable inflammation control for the acute and subacute phases of musculoskeletal injury. The choice between them typically depends on dosing convenience -- naproxen's longer duration allows twice-daily dosing versus ibuprofen's three-to-four-times-daily schedule.

Meloxicam: The Chronic Inflammation Choice

Meloxicam has become one of the most popular prescription NSAIDs in PI practice. Its once-daily dosing, preferential COX-2 activity (providing somewhat lower GI risk than traditional NSAIDs), and effectiveness for chronic inflammatory conditions make it the physician's preferred agent when NSAID therapy will extend beyond the initial acute phase.

Celecoxib: GI Risk Management

Celecoxib is prescribed when the patient has GI risk factors -- history of ulcers, concurrent anticoagulant use, advanced age, or prior GI bleeding -- that make non-selective NSAIDs inappropriate. Its presence in the pharmacy record documents that the physician identified both an inflammatory injury requiring NSAID therapy and a patient risk profile requiring selective COX-2 inhibition.

Ketorolac: Acute Severe Inflammation

Ketorolac is the most potent NSAID available and is typically limited to five days of oral use due to its high GI bleeding risk. It is reserved for acute severe pain and inflammation, often initiated in the emergency department or urgent care setting. Its presence in the pharmacy record signals intense acute inflammatory pain requiring the strongest available NSAID.

Indomethacin: Potent Anti-Inflammatory for Specific Indications

Indomethacin is one of the most potent NSAIDs and is specifically useful for acute inflammatory flares, heterotopic ossification prevention after orthopedic procedures, and gout-like presentations that can occur after traumatic joint injury. Its prescription documents that the physician identified a particularly intense inflammatory component.

Diclofenac: Multi-Route Flexibility

Diclofenac is unique among NSAIDs in being available as oral tablets, topical gel, and topical patches. This multi-route availability makes it valuable in PI when the physician wants to combine systemic and localized anti-inflammatory therapy, or when the patient's GI risk profile makes topical application preferable to oral dosing.

Treatment Escalation Patterns

NSAID escalation patterns in PI cases follow predictable clinical logic:

• OTC ibuprofen/naproxen to Rx-strength -- Self-care insufficient; physician assessment confirms significant inflammation
• Non-selective NSAID to meloxicam -- Transition from acute to chronic management; once-daily dosing for adherence
• Non-selective NSAID to celecoxib -- GI adverse event or GI risk identification; inflammation still requires treatment
• Oral NSAID to ketorolac -- Acute pain crisis; severe inflammatory flare requiring maximum-potency NSAID
• Oral NSAID plus topical diclofenac -- Localized inflammation supplementing systemic therapy; multimodal approach
• NSAID plus GI protective agent -- Documents both ongoing inflammatory injury and appropriate risk management

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The NSAID prescription timeline is the backbone of most PI pharmacy records. When the record shows a progression from OTC naproxen to prescription meloxicam to celecoxib with omeprazole, each change is a physician's documented response to evolving clinical findings -- and each fill date is a timestamp proving ongoing medical necessity."

Defense Challenges and Rebuttals

"NSAIDs are available over the counter -- this is a minor injury"

Rebuttal: The patient's treatment involves prescription-strength NSAIDs, which are clinically distinct from OTC formulations. The physician escalated to prescription strength because clinical examination findings demonstrated inflammation exceeding what consumer-strength products can address. The dosing difference between OTC ibuprofen (200-400 mg) and prescription ibuprofen (800 mg three times daily) is substantial and reflects documented medical necessity.

"The patient could have used generic OTC NSAIDs instead of brand prescription drugs"

Rebuttal: The physician's NSAID selection reflects clinical judgment about the specific anti-inflammatory properties needed. Meloxicam's once-daily dosing and preferential COX-2 activity, celecoxib's GI safety profile, and ketorolac's potency for acute severe pain are not replicated by OTC alternatives. The prescription documents a medical decision, not a consumer choice.

"Long-term NSAID use suggests the injury is chronic and pre-existing"

Rebuttal: Traumatic injuries frequently produce chronic inflammation. Disc herniations, ligamentous injuries, and joint damage from accidents commonly require months of anti-inflammatory therapy. Continued NSAID prescriptions with documented physician visits at each renewal demonstrate ongoing treatment for the traumatic injury, not pre-existing disease management.

Pharmacy Documentation and MERIT Reports

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages. For NSAID cases, the MERIT report captures the complete anti-inflammatory treatment timeline, including escalation patterns, GI protective co-prescriptions, and concurrent medications that corroborate the injury pattern.

The NSAID prescription record, when documented through a structured pharmacy lien program, provides attorneys with objective, timestamped evidence that forms the foundation of the medication cost documentation in demand packages and settlement negotiations.